ICES-based Pulsed Field Electromagnetic Field Therapy for Autoimmunity
基于 ICES 的自身免疫脉冲场电磁场治疗
基本信息
- 批准号:9903662
- 负责人:
- 金额:$ 23.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-06 至 2021-12-31
- 项目状态:已结题
- 来源:
- 关键词:AntigensAutoimmune DiseasesAutoimmunityAutomobile DrivingBiologicalBiophysical ProcessCell MaturationCell physiologyCellsClinicComplexCoupledDataDendritic CellsDevelopmentEffectivenessEffector CellElectric StimulationElectromagnetic FieldsElectromagneticsElectrostaticsEragrostisEventFOXP3 geneFoundationsFutureGoalsHeterogeneityHumanHuman ActivitiesImmuneImmunotherapyInbred NOD MiceInflammationInsulin-Dependent Diabetes MellitusMediatingMindModelingMolecularNatureOrthopedicsPathologyPhenotypePhysiologic pulsePreventionPropertyProteinsPulse RatesRegulatory T-LymphocyteReportingRestSafetySelf ToleranceShapesSignal TransductionSiteT-LymphocyteTestingTherapeuticTissuesWorkacquired immunityautoreactivitybasecell typeclinical applicationcombinatorialdisease heterogeneitydisorder preventioneffector T cellhumanized mouseimmunopathologyimmunoregulationin vivoinnovationinsightisletnanonovelpre-clinicalpreventtool
项目摘要
SUMMARY/ABSTRACT
Human autoimmune diseases such as type 1 diabetes (T1D) are characterized by heterogeneous and complex
events driving immunopathology. To deal with this heterogeneity for disease prevention and treatment, we
need a variety of immunotherapies with distinct mechanisms of action. With this in mind, the goal of our R21
proposal is to establish proof-of-concept that pulsed electromagnetic field (PEMF) therapy is an effective
approach to selectively suppress ongoing autoimmunity, and reestablish self-tolerance. Micro/nano-currents
induced in vivo by PEMF under the appropriate conditions can alter cellular properties. Different types of PEMF
have been successfully and safely applied in the clinic; however, use of PEMF for autoimmunity has not been
tested.
For this study, we are using a unique type of PEMF referred to as inductively coupled electrical stimulation
(ICES). Properties of ICES result in electromagnetic pulses believed to closely mimic native electrical signaling
events that enhance both biological effects and safety. Three Aims are outlined, employing NOD mice a
spontaneous model of T1D, to establish the applicability of ICES-based PEMF to modulate autoimmunity. In
Aim 1, studies will define the tolerogenic effects of ICES on cell-specific T cell reactivity. Aim 2 will focus on
determining ICES effects on dendritic cell maturation and function. In Aim 3 ICES-induced immunoregulation
will be explored, and effects on acquired immunity investigated. This work is expected to establish a foundation
for future studies: 1) to further define the mechanisms by which ICES specifically, and PEMF in general
regulate immune effectors, and 2) to test the clinical application of ICES to prevent and/or treat T1D, as well as
other autoimmune diseases and immune-driven pathologies.
总结/摘要
人类自身免疫性疾病如1型糖尿病(T1 D)的特征在于异质性和复杂性,
推动免疫病理学的事件。为了处理这种异质性,以预防和治疗疾病,我们
需要具有不同作用机制的多种免疫疗法。考虑到这一点,我们的R21的目标
建议是建立概念验证,脉冲电磁场(PEMF)治疗是一种有效的
方法选择性抑制正在进行的自身免疫,并重建自身耐受性。微/纳电流
在适当条件下由PEMF在体内诱导的细胞毒性可以改变细胞特性。不同类型的PEMF
已经成功和安全地应用于临床;然而,使用PEMF治疗自身免疫性疾病还没有被证实。
测试.
在这项研究中,我们使用了一种独特的PEMF,称为感应耦合电刺激
(ICES). ICES的特性导致电磁脉冲被认为与天然电信号非常相似
增强生物效应和安全性的事件。概述了三个目的,采用NOD小鼠和
T1 D的自发模型,以建立基于ICES的PEMF调节自身免疫的适用性。在
目的1,研究ICES对T细胞特异性T细胞反应性的致耐受性作用。目标2将侧重于
确定ICES对树突状细胞成熟和功能的影响。目的3 ICES诱导的免疫调节
将进行探索,并研究对获得性免疫的影响。这项工作有望建立一个基础
未来的研究:1)进一步定义ICES具体的机制,以及一般的PEMF
调节免疫效应物,和2)测试ICES预防和/或治疗T1 D的临床应用,以及
其他自身免疫性疾病和免疫驱动的病理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Roland M Tisch其他文献
Roland M Tisch的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Roland M Tisch', 18)}}的其他基金
Enhancing antigen-based therapy for T1D by T cell coreceptor tuning
通过 T 细胞辅助受体调节增强基于抗原的 T1D 治疗
- 批准号:
10593245 - 财政年份:2022
- 资助金额:
$ 23.33万 - 项目类别:
ICES-based Pulsed Field Electromagnetic Field Therapy for Autoimmunity
基于 ICES 的自身免疫脉冲场电磁场治疗
- 批准号:
10079462 - 财政年份:2020
- 资助金额:
$ 23.33万 - 项目类别:
Thymic and peripheral regulation of autoreactive T cells by coreceptor therapy
共受体治疗对胸腺和外周自身反应性 T 细胞的调节
- 批准号:
10395438 - 财政年份:2019
- 资助金额:
$ 23.33万 - 项目类别:
Thymic and peripheral regulation of autoreactive T cells by coreceptor therapy
共受体治疗对胸腺和外周自身反应性 T 细胞的调节
- 批准号:
10623181 - 财政年份:2019
- 资助金额:
$ 23.33万 - 项目类别:
The role of AIM2 in T cell-mediated autoimmunity
AIM2 在 T 细胞介导的自身免疫中的作用
- 批准号:
10321613 - 财政年份:2019
- 资助金额:
$ 23.33万 - 项目类别:
The role of AIM2 in T cell-mediated autoimmunity
AIM2 在 T 细胞介导的自身免疫中的作用
- 批准号:
10083178 - 财政年份:2019
- 资助金额:
$ 23.33万 - 项目类别:
Combinatorial beta Cell-Specific Cytokine Therapy to Reverse Type I Diabetes
逆转 I 型糖尿病的组合 β 细胞特异性细胞因子疗法
- 批准号:
8911506 - 财政年份:2015
- 资助金额:
$ 23.33万 - 项目类别:
Combinatorial Beta Cell-Specific Cytokine Therapy to Reverse Type I Diabetes
逆转 I 型糖尿病的β细胞特异性细胞因子组合疗法
- 批准号:
9240623 - 财政年份:2015
- 资助金额:
$ 23.33万 - 项目类别:
Islet-Specific Tolerance Induced by T Cell Co-Receptor Therapy in Type 1 Diabetes
T 细胞辅助受体治疗在 1 型糖尿病中诱导的胰岛特异性耐受
- 批准号:
8725412 - 财政年份:2014
- 资助金额:
$ 23.33万 - 项目类别:
Islet-Specific Tolerance Induced by T Cell Co-Receptor Therapy in Type 1 Diabetes
T 细胞辅助受体治疗在 1 型糖尿病中诱导的胰岛特异性耐受
- 批准号:
8829828 - 财政年份:2014
- 资助金额:
$ 23.33万 - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Operating Grants
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
- 批准号:
23H02155 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
- 批准号:
10788032 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
- 批准号:
23K14742 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
- 批准号:
10864719 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
- 批准号:
10586562 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
- 批准号:
10593224 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
- 批准号:
23K06589 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
- 批准号:
10623380 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
- 批准号:
10735148 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别: